Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu-PRRT + Capecitabine in Aggressive GEP-NETs
NCT02736500Phase 2Completed
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Sep 2015
- Primary completion
- Apr 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu 177 dotatate in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Started Sep 2015; status: completed.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT02736500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02736500.